Ligand id: 6770

Name: alemtuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alemtuzumab

Bioactivity Comments
The necleotide sequences for the CAMPATH-1 antibody were originally identified by Crowe et al. (1992) [1], and this article reports the ADCC effector function of the antibody against K422B lymphoma cells. The reported nucleotide sequences were used to generate an antibody with swapped anti-CAMPATH domains, described in patent US7923538 [4]. The constructed antibodies exhibited improved complement-dependent cytotoxic activity (CDC) and antibody-dependent cell-mediated cytotoxic activity (ADCC) compared to Campath1H-IgG. Affinity data for the interaction between the antibody and the CAMPATH-1 antigen is not provided in either the original article or in patent US7923538 [5].
Selectivity at human other protein targets
Key to terms and symbols Click column headers to sort
Target Type Action Affinity Units Concentration range (M) Reference
CD52 Antibody Binding - - - 2,5